Skip to main content
Clinical Trials/NCT05070741
NCT05070741TerminatedNot Applicable

Heat Shock Therapy to Improve Mitochondrial Function in Neuropathy

University of Kansas Medical Center2 sites in 1 country3 target enrollmentStarted: July 27, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
3
Locations
2
Primary Endpoint
Change in Fasting Blood Glucose (FBG)

Study Overview

Brief Summary

Sensory dysfunction as a result of peripheral nerve damage is a significant problem that leads to reduced quality of life for patients. The prevalence of sensory dysfunction in peripheral neuropathy associates with epidemic increases in prediabetes and diabetes, but also is relevant to chemotherapy treatments and genetic disorders. Clinical approaches to treat peripheral neuropathy and to stimulate axon growth in settings of peripheral axon loss are limited. Although new drugs will hopefully be forthcoming, the most promising approaches likely involve behavioral and lifestyle interventions. Mitochondrial dysfunction is emerging as a key cellular contribution to peripheral axon health and peripheral neuropathy. Mitochondrial deficiencies contribute to neuropathy and include impaired mitochondrial problems with trafficking, mitophagy, fission, and biogenesis. All of these are thought to lead to a bioenergetic crisis, ending in distal axonal degeneration, sensory dysfunction and pain. Heat shock proteins play a critically important role in cellular homeostasis and increasing heat shock protein functions within cells leads to a range of positive improvements, particularly in mitochondria. In addition, new evidence suggests that increasing heat shock protein responses in peripheral nerves has powerful, positive impacts on sensory function and neuropathy.

Our interdisciplinary team will investigate the role of mitochondrial dysfunction in peripheral neuropathy and translate these approaches to improve treatment for patients with peripheral neuropathy. The investigators hypothesize that novel heat treatment interventions that improve mitochondrial function will improve metabolic symptoms and peripheral nerve mitochondria, leading to improvements in sensory function, via heat shock protein induction. The investigators will employ immersion heat treatment to elevate heat shock protein responses that induce positive changes in peripheral nerve mitochondria. One aspect is to confirm the efficacy, safety, and potential for heat treatment to improve sensory dysfunction in human patients with prediabetes. The goal of this proposal is 1) to test the breadth of heat treatment on various forms of neuropathy, 2) identify mechanisms in which heat treatment improves mitochondrial function, and 3) test the efficacy, safety, and potential for heat treatment to improve sensory dysfunction in human patients with prediabetes.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
45 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in Fasting Blood Glucose (FBG)

Time Frame: At baseline and post-intervention (~4-5 weeks after first visit)

The study team will measure fasting blood glucose at baseline and post-intervention.

Change in 2-hr Glucose

Time Frame: At baseline and post-intervention (~4-5 weeks after first visit)

The study team will measure 2-hr Glucose at baseline and post-intervention. To complete the oral glucose tolerance test (OGTT), the participant will drink a sweet, concentrated solution of glucose (Azer Scientific Glucola, 75 g) within 5 minutes. Afterwards, the participant will wait 2-hrs and blood will be drawn to test glucose and insulin levels.

Change in Intraepidermal Nerve Fibers (IENF)

Time Frame: At baseline and post-intervention (~4-5 weeks after first visit)

The study team will count intraepidermal nerve fibers at baseline and post-intervention.

Secondary Outcomes

  • Change in Concentration of Heat Shock Protein 72(At baseline and post-intervention (~4-5 weeks after first visit))
  • Change in Quantitative Sensory Testing (QST) Scores(At baseline and post-intervention (~4-5 weeks after first visit))
  • Change in Concentration of Heat Shock Protein 25(At baseline and post-intervention (~4-5 weeks after first visit))
  • Change in Concentration of Heat Shock Protein Transcription Factor 1(At baseline and post-intervention (~4-5 weeks after first visit))
  • Utah Early Neuropathy Scale (UENS)(At baseline and post-intervention (~4-5 weeks after first visit))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Paige Geiger, PhD

Professor of Molecular & Integrative Physiology

University of Kansas Medical Center

Study Sites (2)

Loading locations...

Similar Trials